Ethical statement
All participants provided written informed consent before enrolment in the trial and after the nature and possible consequences of the study were explained. The study was conducted according to the Declaration of Helsinki. The trial protocol was approved on March 09, 2022, by the Ethic Committee in Clinical Research Stambulian (CEIC), and by the Food and Drugs National Regulatory Agency (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, ANMAT), on March 22, 2022. Participants received compensation for their participation by travel costs reimbursement and food during their stay at the facilities.Samples of the surveillance strategy implemented by the Ministry of Health of the Province of Buenos Aires that were used, were obtained from individuals that gave a written informed consent after receiving a fully explanation of the nature and possible consequences of the study. The study was approved on February 3, 2022, by the Central Ethics Committee of Buenos Aires Province (Comité de ética central de la provincia de Buenos Aires).